Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gastrin-17 (often specifically "Little gastrin I" or "Gastrin heptadecapeptide") (Gastrin-17)
- Target
- Gastrin-17
- Molecular classification
- Peptide hormone, Regulatory peptide
01
Overview
Gastrin-17 ("little gastrin") is a 17-amino-acid peptide hormone released predominantly by G cells in the gastric antrum in response to food, vagal stimulation, and luminal peptides/amino acids. Its main biological role is to stimulate secretion of gastric acid by parietal cells through activation of the cholecystokinin B receptor, enhance mucosal cell proliferation, and promote GI motility. It is clinically important as an indicator of gastric function and as a biomarker for gastric diseases, especially conditions with altered acid production and certain gastrointestinal cancers. Gastrin-17 is not itself a drug target but is critical for regulating gastric physiology and is often measured in clinical assays.
- Other names
- Little gastrin IGastrin-17Gastrin heptadecapeptideHeptadecapeptide gastrin
02
Mechanism of action
N/A for drugs directly targeting Gastrin-17. Drugs typically modulate secretion or act on its receptor (CCK2R). For receptor antagonists: block CCKB receptor, thereby inhibiting gastrin-mediated acid secretion
03
Biological functions
Stimulates gastric acid secretionPromotes gastrointestinal mucosal growthStimulates gastric motility
04
Disease associations
Cancer (specifically gastrointestinal malignancies)Hypergastrinemia (e.g., in gastrinomas, *Helicobacter pylori* infection, Zollinger-Ellison syndrome)Gastroesophageal reflux disease (GERD)
05
Safety considerations
Hypochlorhydria (risk with elevated gastrin-17 from acid suppression)Tumorigenesis risk with chronic hypergastrinemia
06
Interacting drugs
None directly for Gastrin-17. However, drugs affecting gastrin secretion include:
3 more in the full profile.
07
Biomarkers
Plasma gastrin-17 levels (used for diagnosis and monitoring of gastric disorders, gastrinomas, monitoring PPI therapy, H. pylori infection)
Beyond the preview
Go deeper on Gastrin-17 (often specifically "Little gastrin I" or "Gastrin heptadecapeptide") (Gastrin-17).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gastrin-17 (often specifically "Little gastrin I" or "Gastrin heptadecapeptide") (Gastrin-17).